Innoviva, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical royalty company that developed respiratory medicines in partnership with GlaxoSmithKline, including the Ellipta inhaler products Breo and Anoro, and now earns ongoing royalties from those drugs. It was born in 2014 when the drug developer Theravance split in two: the research-and-development arm became Theravance Biopharma, while the royalty business took the name Innoviva. The name blends "innovation" and "vival"—a nod to the company's core role of keeping proven medicines alive in the market.
2.125% Note
Bought 663.0K
Granted 253.9K · Bought 49.0K
Granted 1.51M · Sold 321.8K
Granted 2.15M · Bought 20.0K · Sold 1.06M
Granted 67.8K
Granted 550.6K · Sold 256.4K
Granted 405.5K · Bought 41.1K
Granted 481.6K · Sold 37.4K
Granted 466.0K · Sold 96.1K
Granted 355.2K · Sold 29.2K
Granted 277.4K · Bought 3.0K
Granted 305.8K
Granted 196.2K · Sold 53.4K
Granted 270.7K · Sold 3.7K
Granted 74.4K · Sold 39.2K
Granted 171.8K · Sold 16.3K
Granted 140.5K
Granted 140.5K
Granted 140.5K
Granted 92.2K · Bought 45.0K
Granted 108.1K
Granted 67.8K
Granted 61.8K
Granted 92.2K
Granted 100.1K · Sold 16.1K
Granted 58.4K · Sold 38.0K
Granted 73.8K
Granted 73.8K
Granted 73.8K · Sold 3.3K
Granted 48.2K
Granted 58.3K
Granted 86.9K · Sold 17.7K
Granted 54.3K
Granted 33.4K
Granted 52.3K
Granted 504.5K · Sold 451.6K
Granted 35.8K
Granted 30.4K
Granted 42.0K
Granted 12.8K
Granted 37.1K
Granted 36.0K
Granted 24.0K · Sold 82.1K
Granted 33.0K
Granted 20.0K
Granted 15.0K
Granted 5.4K
Granted 10.6K · Sold 10.6K
Bought 22.60M · Sold 32.01M
Granted 14.5K
Granted 15.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Denner Alexander J +1 co-filer10% owner · 10 transactions | — | 14.28Mas of Jun 2023 | — | 663.0K | — |
| Vagelos P RoyDirector · 43 transactions | — | 1.57Mas of Dec 2009 | 253.9K | 49.0K | — |
| Aguiar Michael WPresident & Chief Exec Officer, Director · 66 transactions | — | 980.9Kas of Dec 2017 | 1.51M | — | 321.8K |
| Winningham Rick EDirector · 69 transactions | — | 825.4Kas of Aug 2014 | 2.15M | 20.0K | 1.06M |
| Whitesides George MDirector · 11 transactions | — | 776.7Kas of May 2014 | 67.8K | — | — |
| Shafer Bradford JSr VP, Gen. Counsel, Secretary · 115 transactions | — | 445.8Kas of Aug 2014 | 550.6K | — | 256.4K |
| Blum Leonard MSr VP, Chief Comm. Officer · 30 transactions | — | 401.5Kas of Aug 2014 | 405.5K | 41.1K | — |
| dEsparbes EricSVP and CFO · 25 transactions | — | 373.1Kas of May 2018 | 481.6K | — | 37.4K |
| Mammen MathaiSVP, Research & Early Clin Dev · 63 transactions | — | 334.0Kas of Aug 2014 | 466.0K | — | 96.1K |
| Abercrombie George BSr. VP & Chief Comm. Officer · 20 transactions | — | 285.5Kas of Aug 2018 | 355.2K | — | 29.2K |
| Raifeld PavelChief Executive Officer, Director · 9 transactions | — | 284.8K | 277.4K | 3.0K | — |
| Faerm Michael E.Sr VP & Chief Business Officer · 9 transactions | — | 279.4Kas of Nov 2017 | 305.8K | — | — |
| Lee JunningSr. VP, Technical Operations · 13 transactions | — | 262.2Kas of Aug 2014 | 196.2K | — | 53.4K |
| Witek Theodore L JrSr. VP & Chief Scientific Off. · 8 transactions | — | 260.1Kas of Jan 2017 | 270.7K | — | 3.7K |
| Witek Theodore J. Jr.Sr. VP & Chief Scientific Off. · 12 transactions | — | 247.8Kas of Aug 2018 | 74.4K | — | 39.2K |
| Waltrip William HDirector · 15 transactions | — | 161.8Kas of Apr 2017 | 171.8K | — | 16.3K |
| Haimovitz JulesDirector · 10 transactions | — | 152.7K | 140.5K | — | — |
| DiPaolo MarkDirector · 10 transactions | — | 140.5K | 140.5K | — | — |
| Schlesinger Sarah J.Director · 10 transactions | — | 140.5K | 140.5K | — | — |
| Bickerstaff GeorgeDirector · 10 transactions | — | 137.2Kas of Apr 2022 | 92.2K | 45.0K | — |
| Odysseas Kostas DDirector · 7 transactions | — | 122.6Kas of Jun 2024 | 108.1K | — | — |
| Gunderson Robert V JRDirector · 9 transactions | — | 121.7Kas of May 2014 | 67.8K | — | — |
| Levine Arnold JDirector · 19 transactions | — | 111.8Kas of Mar 2014 | 61.8K | — | — |
| Basso StephenChief Financial Officer · 15 transactions | — | 88.0K | 92.2K | — | — |
| Young William DDirector · 14 transactions | — | 83.9Kas of May 2014 | 100.1K | — | 16.1K |
| Kitt MichaelSr. Vice President Development · 57 transactions | — | 75.1Kas of Jun 2008 | 58.4K | — | 38.0K |
| Friedman CathyDirector · 6 transactions | — | 73.8Kas of Apr 2017 | 73.8K | — | — |
| Pepe PaulDirector · 6 transactions | — | 73.8Kas of Apr 2017 | 73.8K | — | — |
| Tyree James LDirector · 8 transactions | — | 70.6Kas of Apr 2017 | 73.8K | — | 3.3K |
| Birx DeborahDirector · 4 transactions | — | 59.0Kas of May 2023 | 48.2K | — | — |
| Lepore Patrick GDirector · 2 transactions | — | 58.3Kas of Apr 2017 | 58.3K | — | — |
| Zhen MarianneChief Accounting Officer · 49 transactions | — | 56.4K | 86.9K | — | 17.7K |
| Humphrey Patrick PAExecutive VP Research · 3 transactions | — | 55.0Kas of Dec 2007 | 54.3K | — | — |
| Hulme GeoffreyInterim Principal Exec Officer · 5 transactions | — | 53.3Kas of May 2020 | 33.4K | — | — |
| Duncan Barbara GayleDirector · 2 transactions | — | 52.3Kas of Apr 2017 | 52.3K | — | — |
| Brinkley David LHead of Business Dev. · 108 transactions | — | 48.7Kas of May 2013 | 504.5K | — | 451.6K |
| Small Derek ADirector · 3 transactions | — | 45.0K | 35.8K | — | — |
| Srivastava SapnaDirector · 2 transactions | — | 44.1Kas of Jun 2024 | 30.4K | — | — |
| Malkiel Burton GDirector · 9 transactions | — | 41.0Kas of May 2014 | 42.0K | — | — |
| Ronsheim MatthewSee Remarks · 4 transactions | — | 40.5Kas of May 2024 | 12.8K | — | — |
| Kearney Terrence CDirector · 2 transactions | — | 37.1Kas of Apr 2015 | 37.1K | — | — |
| Ringrose Peter SDirector · 5 transactions | — | 36.0Kas of May 2014 | 36.0K | — | — |
| Drazan Jeffrey MDirector · 24 transactions | — | 33.5Kas of May 2012 | 24.0K | — | 82.1K |
| Fore HenriettaDirector · 6 transactions | — | 33.0Kas of May 2014 | 33.0K | — | — |
| Pasqualone FrankSr. Vice President, Operations · 1 transaction | — | 20.0Kas of Jan 2014 | 20.0K | — | — |
| Jonker Jeffrey DavidSenior VP, Corp. & Bus. Dev. · 1 transaction | — | 15.0Kas of Oct 2013 | 15.0K | — | — |
| Campbell Arthur LSr. VP, Technical Operations · 1 transaction | — | 5.4Kas of Jan 2008 | 5.4K | — | — |
| Loewenthal RonnDirector · 20 transactions | — | 5.2Kas of May 2006 | 10.6K | — | 10.6K |
| Glaxosmithkline PLC10% owner · 22 transactions | — | 0as of May 2021 | — | 22.60M | 32.01M |
| Kostas Odysseas DDirector · 1 transaction | — | 0as of Dec 2017 | 14.5K | — | — |
| Linden JosephineDirector · 2 transactions | — | 0 | 15.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -11.12M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.